Uterine Cancer

New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma

2023-08-20

  • Study

    Single-arm, open-label, multicenter, phase II trial
    Patients with uLMS, progression on ≥1 prior line treatment
    Temozolomide +Olaparib (n=22


  • Efficacy

    cORR: 27.0% [6 of 22 pts]
    mPFS: 6.9 mos [5.4-NR], İTT population
    mPFS:11.2 vs. 5.4 mos, HRD and HRP, respectively

  • Safety

    Grade3: Neutropenia (65%), thrombocytopenia (32%), leukopenia (22%).


    • Journal of Clin Oncol 19 JUL, 2023

    Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)

    http://doi.org/10.1200/JCO.23.00402

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023